Discusses the role of PKG inhibitors in attenuating platelet aggregation.
May not alter antiplatelet practice; leaves open PKG as antithrombotic target pending clinical validation.
Within recent correspondence[1][1],[2][2] concerning the roles of cyclic guanosine monophosphate (cGMP)/cGMP–dependent protein kinase (cGK or PKG), Du et al[1][1](p4371) state that their data[3][3],[4][4] and ours[5][5] “clearly show that PKG inhibitors attenuate platelet aggregation induced by
No takes yet. Share an insight, caveat, or question.
Walter et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: